Clinical trials: Antiviral Treatment
Idiopathic Trigeminal Neuralgia
Efficacy and Safety of Oral Antiviral Therapy for Idiopathic Trigeminal Neuralgia
This is a multicenter, prospective, randomized, controlled trial. A total of 165 patients with idiopathic trigeminal neuralgia will be enrolled and randomly divided into three groups at a 1:1:1 ratio.
- Trial name
- ANT-TN (NCT07673549)
- Testing
- Intervention：Drug: Carbamazepine, Intervention：Drug: Carbamazepine + Acyclovir, Intervention：Drug: Carbamazepine + Celecoxib
- Volunteers
- 165 people
- Sponsor
- Beijing Tiantan Hospital
HIV Infection
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
This study will continue to follow children who participated in an earlier National Cancer Institute trial of HIV treatment with a protease inhibitor.
- Trial name
- NCT00001826
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HCV Infection
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
The purpose of this study is to determine whether a 3-day course of therapy with orally administered VCH-916 given at different dosages can effectively reduce the amount of circulating virus (i.e., viral load) in patients with…
- Trial name
- NCT00623649
- Testing
- VCH 916
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C
The pathogenesis of chronic hepatitis C (CHC) is associated to severe oxidative stress and non-selective immunological disturbance that leads to necro-inflammation and progression of fibrosis.
- Trial name
- NCT00778843
- Testing
- Viusid
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Cytomegalovirus Anterior Uveitis
Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes
Cytomegalovirus (CMV) is generally a latent and asymptomatic infection in healthy, immunocompetent individuals. In immunocompromised patients CMV is well known to cause a retinitis that can lead to blindness.
- Trial name
- STACCATO (NCT03586284)
- Testing
- Valganciclovir Hydrochloride, Ganciclovir Sodium
- Where
- 4 sites in United States, Thailand
- Volunteers
- 51 people
- Sponsor
- University of California, San Francisco
HIV Infections
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To evaluate the immunologic effects of zidovudine and ddI or ddC.
- Trial name
- NCT00002001
- Testing
- Zidovudine, Zalcitabine, Didanosine
- Where
- 5 sites in United States, Australia and 1 more
- Sponsor
- Glaxo Wellcome
Hepatitis D
Pegylated Interferon to Treat Chronic Hepatitis D
This study will evaluate the safety and effectiveness of a long-acting form of alpha interferon called pegylated interferon in treating hepatitis D virus (HDV) infection.
- Trial name
- NCT00023322
- Testing
- Peginterferon Alpha-2a
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Respiratory Synctial Virus Infections
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in…
- Trial name
- NCT06775405
- Testing
- AK0529
- Where
- 17 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Infection, Human Immunodeficiency Virus I, HIV Infection
GW873140 In Combination With Combivir In HIV Infected Subjects
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.
- Trial name
- NCT00104429
- Testing
- GW873140, Combivir
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 125 people
- Sponsor
- ViiV Healthcare
Anemia, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo for the treatment of anemia in AIDS (Acquired Immunodeficiency Syndrome) patients with anemia that is a result of this disease…
- Trial name
- NCT00269945
- Testing
- epoetin alfa
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hepatitis C, Chronic
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®)…
- Trial name
- NCT01271790
- Testing
- Tegobuvir (GS-9190), GS-9451, Pegasys®
- Where
- 144 sites in United States, Austria and 6 more
- Volunteers
- 245 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus, Disorder of Immune Reconstitution
Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
HIV-1 infection is characterized by progressive depletion of CD4+ T cells that eventually leads to clinically significant immunodeficiency.
- Trial name
- NCT01213186
- Testing
- high dose of MSC, low dose of MSC treatment
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Fu-Sheng Wang
HIV
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
- Trial name
- NCT00634959
- Testing
- Maraviroc (UK-427,857)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis B Infection
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03210493
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis C
Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)
This is a multi-center, open-label clinical study. This study was aimed to assess the real-world effectiveness and safety of treatment with listed DAAs in patients with CHC and cirrhosis in Southern area of China.
- Trial name
- NCT03887637
- Testing
- DAAs
- Volunteers
- 180 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Hepatitis C, Chronic
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
SHARP-P is an observational cohort study investigating the effect of direct-acting antiviral (DAA) therapy and reinfection in people with chronic hepatitis C virus (HCV) and recent injecting drug use.
- Trial name
- SHARP-P (NCT03740906)
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C, Pharmacokinetics
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
The current Standard of Care (SOC) for chronic HCV infection, which is pegylated interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is effective in only part of the patients and is often…
- Trial name
- NCT00947349
- Testing
- ribavirin (RBV), pegylated interferon (PegIFN) alfa-2a, BI 201335 NA high
- Where
- 3 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
HIV-1 Infection, Hepatitis C
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir.
- Trial name
- NCT02605304
- Testing
- Ledipasvir/sofosbuvir, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection, Hepatitis C, Chronic
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current…
- Conditions
- HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence, Opioid Dependence
- Trial name
- NCT03549312
- Testing
- Genvoya, Epclusa, Biktarvy
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area